Hilo (formerly known as Aktiia), has raised $42m (SFr34.7m) in an oversubscribed Series B funding round, bringing its total funding to more than $100m.
The Swiss 24/7 blood pressure monitoring system developer’s latest funding round was co-led by Earlybird Health and joined by new investors Kfund and naturalX Health Ventures. Existing investors including Molten Ventures and Translink Capital also took part.
Go deeper with GlobalData
The blood pressure monitoring bracelet uses optical sensors and AI-based algorithms to measure blood pressure through Optical Blood Pressure Monitoring (OBPM), a process that involves analysing subtle changes in the diameter of arteries with each heartbeat.
The latest funding tranche, which Hilo said would support ongoing product innovation and expansion into new markets, comes at a busy time for the company.
Hilo’s blood pressure monitoring bracelet launched in Canada last year, with the approval from Health Canada marking Hilo’s first market expansion outside of Europe since receiving a CE mark on the bracelet in 2021. Regulatory approvals on the bracelet have also recently been secured in Australia and Saudi Arabia.
Also in 2024, the company gained CE marking for its optical blood pressure measuring technology without the need for calibration from a traditional cuff, opening the door for the integration of its technology into commercial smartwatches and phones.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHilo recently also completed a pivotal clinical trial validating its OBPM approach to blood pressure monitoring which it stated would support a future application with the US Food and Drug Administration.
Hilo CEO Raghav Gupta called the latest fund raise a testament to the confidence its investors have in its technology and its aims to manage users’ blood pressure via “more frequent, convenient and accurate measurements”.
“With billions worldwide suffering from hypertension, only 20% of whom are in control of their blood pressure, the need for innovative, accessible blood pressure monitoring solutions has never been greater.”
Commenting on the company’s rebrand, Gupta said that Hilo represents more than just a name change.
“It’s a commitment to empowering users around the world with smarter tools to optimise their health.”
Earlybird Health principal Christoph Massner, who will now join Hilo’s board, said: “Hilo stands at the intersection of medical-grade precision and consumer-centric accessibility. By building on a validated medical device platform and an intuitive, user-friendly design, they bridge the gap between clinical reliability and everyday usability.”
